All peptides
SARM

GW-501516

Also known as: Cardarine, Endurobol

preclinical onlyWADA bannedNot FDA approvedResearch only
Mechanism of Action

GW-501516, also called cardarine, is a PPAR-delta receptor agonist. Human lipid and metabolic studies support PPAR-delta pathway activity, but development stopped and safety concerns remain, so ProtoComp should frame it as investigational metabolic context with strong caution.

Key Citations
Published Dose Range
Low10 mg/day
Typical10-20 mg/day
High20 mg/day

PPAR-δ agonist (not a true SARM). Development was halted after long-term animal studies showed accelerated tumor formation across multiple organ systems at high doses.

Published Cycle Range
Short4 wks
Typical8 wks
Long12 wks

Short cycles only. Long-term carcinogenicity signal in animal data is the primary safety concern.

Off-cycle: 4 weeks

Administration
Routesoral
FrequencyOnce daily
Preferred timingPre-workout

Half-life ~24 hours.

Safety Profile

Contraindications

  • History of cancer
  • Family history of cancer
  • Liver disease
  • Pregnancy

Common side effects

  • Mild GI upset
  • Headache

Serious risks

  • Cancer signal — long-term rodent studies showed tumors in multiple organs at high doses
  • Development halted by GSK for this reason

Pregnancy / breastfeeding

Contraindicated

Common Misconceptions
  • Not a SARM — PPAR-δ agonist
  • Non-hormonal, but the cancer signal is the real concern, not suppression
Commonly Stacked With
MK-2866
  • Short-duration use due to carcinogenicity signal in preclinical data
Next Steps

Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.

Reference information only. Always confirm with your clinician before changing your protocol.